Pharmacological treatment of heterotopic ossification following hip and acetabular surgery

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 767-786

  Macfarlane, Robert J ^a   Ng, Boon Han ^a   Gamie, Zakareya ^a   El Masry, Mohamed A ^a   Velonis, Stylianos ^a   Schizas, Constantin ^a   Tsiridis, Eleftherios ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Acetabular surgery; Heterotopic ossification; Ph; Total hip arthroplasty

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETIDRONIC ACID; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOROLAC; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; TENOXICAM; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ACETABULUM FRACTURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; DYSPEPSIA; EVIDENCE BASED MEDICINE; FLATULENCE; FRACTURE NONUNION; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HEART INFARCTION; HEARTBURN; HEMATOMA; HETEROTOPIC OSSIFICATION; HUMAN; IRRADIATION; JOINT LIMITATION; LOW DRUG DOSE; NAUSEA; NAUSEA AND VOMITING; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PROPHYLAXIS; RADIATION DOSE; REVIEW; SINGLE DRUG DOSE; TOTAL HIP PROSTHESIS; TREATMENT DURATION; VOMITING; WOUND COMPLICATION; ACETABULUM; HIP ARTHROPLASTY; POSTOPERATIVE COMPLICATION;

ACETABULUM; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; DICLOFENAC; HUMANS; INDOMETHACIN; NAPROXEN; OSSIFICATION, HETEROTOPIC; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; SULFONAMIDES;

EID: 41949124652     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.767     Document Type: Review

References (100)

1. Vanden Bossche L, Vanderstraeten G. Heterotopic ossification: a review. J Rehabil Med 2005;37(3):129-36
2. Soballe K, Christensen F, Kristensen SS. Ectopic bone formation after total hip arthroplasty. Clin Orthoped Rel Res 1988;228:57-62
3. Tozun R, Pinar H, Yeiller E, Hamzaolu A. Indomethacin for prevention of heterotopic ossification after total hip arthroplasty. J Arthroplast 1992;7(1):57-61
4. Schmidt SA, Kjaersgaard-Andersen P, Pedersen NW, et al. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg Am 1988;70(6):834-8
5. McMahon JS, Waddell JP, Morton J. Effect of short course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplast 1991;6(3):259-64
6. Liebergall M, Mosheiff R, Low J, et al. Acetabular fractures. Clinical outcome of surgical treatment. Clin Orthoped Rel Res 1999;(366):205-16
7. Giannoudis PV, Grotz MR, Papakostidis C, Dinopoulos H. Operative treatment of displaced fractures of the acetabulum. A meta-analysis. J Bone Joint Surg Br 2005;87(1):2-9
8. Kinik H, Armangil M. Extensile triradiate approach in the management of combined acetabular fractures. Arch Orthoped Trauma Surg 2004;124(7):476-82
9. Johnson EE, Kay RM, Dovey FJ. Heterotopic ossification prophylaxis following operative treatment of acetabular fractures. Clin Orthoped 1994;305:20-30
10. Fahrer H, Koch P, Ballmer P, et al. Ectopic ossification following total hip arthroplasty: is diffuse idiopathic skeletal hyperostosis a risk factor? Br J Rheumatol 1988;27(3):187-90
11. Bundrick TJ, Cook DE, Resnik CS. Heterotopic bone formation in patients with DISH following total hip replacement. Radiology 1985;155(3):595-7
12. Ferguson DJ, Itonaga I, Maki M, et al. Heterotopic bone formation following hip arthroplasty in Paget's disease. Bone 2004;34(6):1078-83
13. Blasingame JP, Resnick D, Coutts RD, Danzig LA. Extensive spinal osteophytosis as a risk factor for heterotopic bone formation after total hip arthroplasty. Clin Orthoped Rel Res 1981;(161):191-7
14. Errico TJ, Fetto JF. Waugh TR. Heterotopic ossification. Incidence and relation to trochanteric osteotomy in 100 total hip arthroplasties. Clin Orthoped Rel Res 1984;(190):138-41
15. Sodemann B, Persson PE, Nilsson OS. Periarticular heterotopic ossification after total hip arthroplasty for primary coxarthrosis. Clin Orthoped Rel Res 1988;(237):150-7
16. Ahrengart L, Lindgren U. Heterotopic bone after hip arthroplasty. Defining the patient at risk. Clin Orthoped Rel Res 1993;(293):153-9
17. Morrey BF, Adams RA, Cabanela ME. Comparison of heterotopic bone after anterolateral, transtrochanteric, and posterior approaches for total hip arthroplasty. Clin Orthoped Rel Res 1984;(188):160-7
18. Eggli S, Woo A. Risk factors for heterotopic ossification after in total hip arthroplasty. Arch Orthoped Trauma Surg 2001;121(9):531-5
19. Pai VS. Heterotopic ossification in total hip arthroplasty. The influence of the approach. J Arthroplast 1994;9(2):199-202
20. Ghalambor N, Matta JM, Bernstein L. Heterotopic ossification following operative treatment of acetabular fractures: an analysis of risk factors. Clin Orthoped Rel Res 1994;305:96-105
21. Moed BR, Maxey JW. The effect of indomethacin on heterotopic ossification following acetabular fracture surgery. J Orthoped Trauma 1993;7(1):33-8
22. Triantaphillopoulos PG, Panagiotopoulos EC, Mousafiris M, et al. Long-term results in surgically treated acetabular fractures through the posterior approaches. J Trauma 2007;62(2):378-82
23. Griffin DB, Beaule PE, Matta JM. Safety and efficacy of the extended iliofemoral approach in the treatment of complex fractures of the acetabulum. J Bone Joint Surg Br 2005;87(10):1391-6
24. Roetman B, Seybold D, Keil D, et al. Long-term results after acetabular fractures with respect to heterotopic ossifications. Zentral Chir 2006;31(3):188-93
25. Neal B, Gray H, Macmahon S, Dunn L. Incidence of heterotopic bone formation after major hip surgery. Aust NZ J Surg 2002;72(11):808-21
26. Higo T, Mawatari M, Shigematsu M, Hotokebuchi T. The incidence of heterotopic ossification after cementless total hip arthroplasty. J Arthroplast 2006;21(6):852-6
27. Pohl F, Seufert J, Tauscher A, et al. The influence of heterotopic ossification on functional status of hip joint following total hip arthroplasty. Strahlenther Onkol 2005;181(8):529-33
28. Kan L, Hu M, Gomes WA, Kessler JA. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressive (FOP)-like phenotype. Am J Pathol 2004;165(4):1107-15
29. Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med 1985;26:125-32
30. Kaplan FS, Glaser DL, Shore EM, et al. Haemopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am 2007;89(2):347-57
31. Urist MR, Nakagawa M, Nakata N, Nagami H. Experimental myositis ossificans: cartilage and bone formation in muscle in response to diffusible bone matrix-derived morphogen. Arch Pathol Lab Med 1978;102(6):312-6
32. Glaser DL, Economides AN, Wang L, et al. In vivo somatic gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003;85A(12):2332-42
33. Hannallah D,Peng H,Young B, et al. Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralised bone matrix, and trauma in an animal model. J Bone Joint Surg Am 2004;86A(1):80-91
34. Bartlett CS, Rapuano BE, Lorich DG, et al. Early changes in prostaglandins precede bone formation in a rabbit model of heterotopic ossification. Bone 2006;38(3):322-32
35. Michelsson JE, Juntunen S, Valtakari T, Mikkola J. Methylprednisolone has a preventive effect on heterotopic bone formation and on knee thickening and stiffening following manipulation of immobilized rabbit legs. Clin Exp Rheumatol 1994;12(4):409-13
36. Ahrenhart L, Lindgren U, Reinholt FP. Comparative study of the effects of radiation, indomethacin, prednisolone, and ethane-1-hydroxy-1,1-diphosphonate (EHDP) in the prevention of ectopic bone formation. Clin Orthoped Rel Res 1988;229:265-73
37. Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthrit Res Ther 2005;7(Suppl 4):S14-A22
38. Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement: incidence and a method of classification J Bone Joint Surg Am 1973;55A:1629-32
39. Schmidt J, Hackenbroch MH. A new classification for herterotopic ossification in total hip arthroplasty considering the surgical approach. Arch Orthoped Trauma Surg 1996;115:339-43
40. Board TN, Karva A, Board RE, et al. The prophylaxis and treatment of heterotopic ossification following lower limb arthroplasty. J Bone Joint Surg Br 2007;89B:434-40
41. Burd TA, Lowry KJ, Anglen JO. Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures. J Bone Joint Surg Am 2001;83A(12):1783-8
42. Kienapfel H, Koller M, Wust A, et al. Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Arch Orthoped Trauma Surg 1999;119(5/6):296-302
43. Kjaersgaard-Andersen P, Schmidt SA. Indomethacin for prevention of ectopic ossification after hip arthroplasty. Acta Orthoped 1986;57(1):12-4
44. Schmidt SA, Kjaersgaard-Andersen P. Indomethacin inhibits the recurrence of excised ectopic ossification after hip arthroplasty. A 3-4 year follow-up of 8 cases. Acta Orthoped 1988;59(5):593
45. Vastel L, Kerboull L, Dejean O, et al. Prevention of heterotopic ossification in hip arthroplasty. The influence of the duration of treatment. Int Orthoped 1999;23(2):107-10
46. Van Der Heide HJ, Koorevaar RT, Schreurs BW, et al. Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. J Arthroplast 1999;14(7):796-9
47. Randelli G, Romano CL. Prophylaxis with indomethacin for heterotopic ossification after Chiari osteotomy of the pelvis. J Bone Joint Surg Am 1992;74(9):1344-6
48. Wick M, Muller EJ, Hahn MP, Muhr G. Surgical excision of heterotopic bone after hip surgery followed by oral indomethacin application: is there a clinical benefit for the patient? Arch Orthoped Trauma Surg 1999;119(3/4):151-5
49. Kolbl O, Knelles D, Barthel T, et al. Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement. Int J Radiat Oncol Biol Phys 1997;39(5):961-6
50. Wurnig C, Auersperg V, Boehler N, et al. Short term prohylaxis against heterotopic bone after cementless hip replacement. Clin Orthoped Rel Res 1997;(334):175-83
51. Knelles D, Barthel T, Karrer A, et al. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg Am 1997;79(4):596-602
52. Moed BR, Karges DE. Prophylactic indomethacin for the prevention of heterotopic ossification after acetabular fracture surgery in high-risk patients. J Orthoped Trauma 1994;8(1):34-9
53. McLaren AC. Prophylaxis with indomethacin for heterotopic bone after open reduction of fractures of the acetabulum. J Bone Joint Surg Am 1990;72(2):245-7
54. Moore KD, Goss K, Anglen JO. Indomethacin versus radiation therapy For prophylaxis against heterotopic ossification in acetabular Fractures: a randomized, prospective study. J Bone Joint Surg Br 1998;80(2):259-63
55. Matta JM, Siebenrock KA. Does indomethacin reduce heterotopic bone formation after operations for acetabular fractures? A prospective randomized study. J Bone Joint Surg Br 1997;79(6):959-63
56. Moed BR, Letournel E. Low-dose irradiation and indomethacin prevent heterotopic ossification after acetabular fracture surgery. J Bone Joint Surg Br 1994;76B(6):895-900
57. Pakos EE, Pitouli EJ, Tsekeris PG, et al. Prevention of heterotopic ossification in high-risk patients with total hip arthroplasty: the experience of a combined therapeutic protocol. Int Orthoped 2006;30(2):79-83
58. Knights KM, Tsoutsikos P, Miners JO. Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity. Exp Opin Drug Metab Toxicol 2005;1(3):399-408
59. Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. Immunol Allergy Clin North Am 2005;25(1):169-90
60. Altman RD, Latta LL, Keer R, et al. Effect of nonsteroidal anti-inflammatory drugs on fracture healing: a laboratory study in rats. J Orthopd Trauma 9(5):392-400
61. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 2003;85(5):700-5
62. Ince A, Sauer U, Wollmerstedt N, Hendrich C. No migration of acetabular cups after prophylaxis for heterotopic ossification. Clin Orthoped Rel Res 2007;461:125-9
63. Gebuhr P, Wilbek H, Soelberg M. Naproxen for 8 days can prevent heterotopic ossification after hip arthroplasty. Clin Orthoped Rel Res 1995;(314):166-9
64. Vielpeau C, Joubert JM, Hulet C. Naproxen in the prevention of heterotopic ossification after total hip replacement. Clin Orthoped Rel Res 1999;(369):279-88
65. Romano CL, Duci D, Romano D, et al. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplast 2004;19(1):14-8
66. Saudan M, Saudan P, Pemeger T, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomized trial. J Bone Joint Surg Am 2007;89(2):155-9
67. Simon AM, O'Connor JP. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am 2007;89(3):500-11
68. Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement. Acta Othoped 2007;78(1):95-8
69. Van Der Heide H, Rijberg W, Van Sorge A, et al. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthoped 2007;78(1):90-4
70. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patient with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343(21):1520-8 (with 2 pp. following p. 1528)
71. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364(9450):2021-9
72. Reis HJ, Kusswetter W, Schellinger T. The suppression of heterotopic ossification after total hip arthroplasty. Int Orthoped 1992;16(2):140-5
73. Jockheck M, Willms R, Volkmann R, et al. Prevention of periarticular heterotopic ossification after endoprosthetic hip joint replacement by means of diclofenac. Arch Orthoped Trauma Surg 1998;117(6/7):337-40
74. Sell S, Phillips O, Handel M. No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip arthroplasty. Acta Orthoped 2004;75(1):45-9
75. Sell S, Willms R, Jany R, et al. The suppression of heterotopic ossifications: radiation versus NSAID therapy - a prospective study. J Arthroplast 1998;13(8):854-9
76. Handel M, Phillips O, Anders S, et al. Dose-dependent efficacy of diclofenac-cholestyramine on pain and periarticular ossifications after total hip arthroplasty: a double-blind, prospective, randomized trial. Arch Orthoped Trauma Surg 2004;124(7):483-5
77. Elmstedt E, Lindholm TS, Nilsson OS, Tornkvist H. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthoped 1985;6(1):25-7
78. Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty. A randomized, double-blind prospective study of treatment time. Acta Orthoped 1998;9(2):111-5
79. Koorevaar CT, Hu HP, Lemmens A, Van Kampen A. No effective prophylaxis of heterotopic ossification with short-term ibuprofen. Arch Orthoped Trauma Surg 1999;119(3/4):183-5
80. Ahrengart L, Blomgren G, Tornkvist H. Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthoped 1994;65(2):139-41
81. Fransen M, Anderson C, Douglas J, et al. Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ 2006;333(7567):519
82. Persson PE, Nilsson OS, Berggren AM. Do non-steroidal anti-inflammatory drugs cause endoprosthetic loosening? A 10-year follow-up of a randomized trial an ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthoped 2005;76(6):735-40
83. Pagnani MJ, Pellicci PM, Salvati EA. Effect of aspirin on heterotopic ossification after total hip arthroplasty in men who have osteoarthrosis. J Bone Joint Surg Am 1991;73(6):924-9
84. Kjaersgaard-Andersen P, Ritter MA. Short-term treatment with nonsteroidal antiinflammatory medications to prevent heterotopic bone formation after total hip arthroplasty. A preliminary report. Clin Orthoped Rel Res 1992;(279):157-62
85. Neal BC, Rodgers A, Gray H, et al. No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: a randomized trial of 2,649 patients. Acta Orthoped 2000;71(2):129-34
86. Pritchett JW. Ketorolac prophylaxis against heterotopic ossification after hip replacement. Clin Orthoped Rel Res 1995;(314):162-5
87. Gebuhr P, Sletgard J, Dalsgard J, et al. Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips. Acta Orthoped 1996;67(1):29-32
88. Burssens A, Thiery J, Kohl P, et al. Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. Acta Orthoped 1995;61(3):205-11
89. Hoikka V, Lindholm TS, Eskola A. Flurbiprofen inhibits heterotopic bone formation in total hip arthroplasty. Arch Orthoped Trauma Surg 1990;109(4):224-6
90. Barthel T, Baumann B, Noth U, Eulert J. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthoped 2002;73(6):611-4
91. Fleisch H. Diphosphonates: history and mechanisms of action. Metab Bone Dis Rel Res 1981;3(4/5):279-87
92. Plasmans CM, Kuypers W, Sloof TJ. The effect of ethane-1-hydroxy-1,1-diphosphonic acid (EHDP) on matrix induced heterotopic bone formation. Clin Orthoped Rel Res 1978;(132):233-43
93. Walton M. The effects of long term administration of ethane-1-hydroxy-1,1-diphosphonate on osteoarthritis and heterotopic ossification in the mouse knee joint. Clin Orthoped Rel Res 1981;(155):218-23
94. Hu HP, Kuijpers W, Sloof TJ, et al. The effect of biphosphonate on induced heterotopic bone. Clin Orthoped Rel Res 1991;(272):259-67
95. Ruther W, Kindermann D, Gebhardt M, Munzenberg KJ. Effects of propane-2,2-diphosphonate (PDP) an matrix induced ectopic bone formation in comparison to ethane-1-hydroxy-1,1-diphosphonate (EHDP). Clin Orthoped Rel Res 1990;(258):122-34
96. Stover SL, Niemann KM, Miller III JM. Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal cord injury patients. J Bone Joint Surg Am 1976;58(5):683-8
97. Spielman G, Gennarelli TA, Rogers CR. Disodium etidronate: its role in preventing heterotopic ossification in severe head injury. Arch Phys Med Rehabil 1983;64(11):539-42
98. Nollen AJ. Effects of ethylhydroxydiphosphonate (EHDP) on heterotopic ossification. Acta Orthoped 1986;57(4):358-61.99
99. Thomas BJ, Amstutz HC. Results of the administration of diphosphonate for the prevention of heterotopic ossification after total hip arthroplasty. J Bone Joint Surg Am 1985;67(3):400-3
100. Yutani Y, Ohashi H, Nishimura N, Yamano Y. Clinical effect of etidronate disodium (EHDP) on heterotopic ossification following total hip arthroplasty. Osaka City Med J 1995;41(2):63-7